Bruker to Acquire Oncovision Preclinical PET Imaging Business

Both the companies have also worked together on a high-performance preclinical 3 Tesla SiPM-PET/MRI system.

Dr. Wulf I. Jung, President of Bruker's Preclinical Imaging Division, stated, "With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations."

Dr. Jung added, "This unique and proprietary PET technology is one of the most important imaging modalities for translational research imaging. Our successful collaboration with Oncovision has led to the recent introduction of the performance-leading Albira Si PET/SPECT/CT system, and it now has also resulted in the first PET insert for high-field MRI systems for simultaneous PET and MRI measurements."

Ignasi Vivas, CEO of Oncovision, said, "Bruker is the undisputed leader in preclinical imaging with a unique portfolio of imaging modalities. Our preclinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of our molecular imaging technologies, and fulfill the growing demand from translational scientists."

Related Links:
Bruker
Oncovision